RE:Best in class 2and 3 year dataThanks Enriquesuave, good post.
1) You are correct, TLT 21.4% at 3 years is huge compared to J&J Tar-200(4.7%).
2) In this link...
.
Study Details | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Gurin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | ClinicalTrials.gov Under '' How is the study designed (Participant Group/Arm'').
It said '' Tar-200 will be dosed every 3 weeks(Q3W) for up to 24 weeks(6 months), then every 12 weeks through Week 99''.
Tar-200 is not exactly a ''
One And Done Treatment'' like TLT-Ruvidar.
3) Johnson & Johnson Tar-200 is another very good exemple of a Big Pharma Company, that in spite of having a huge market cap of 388 BillionUS, J&J could not come up with a decent'' One And Done Treatment'' for BCG resistant patients.
Question?
Could it be possible, that as we speak, many of these hundred billion$ Big Pharma Company, are already talking with D.Lbiati???
enriquesuave wrote: so far we beat all competitors on 2 and 3 year data and by far. J&J tar 200 is down to 4.7% at 3 years and we are aiming for 21.4% as per Kaplan Meyer projections so far.. This shows how all other treatments show rapidly declining CR rates once they stop treating. We also beat 2 years data of recently approved combination treatment Anktiva/ BCG. 24%% vs 25.6% for us based on Kaplan Meyer projection. Can the FDA give us AA or even full approval right away?